Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin
Top Cited Papers
- 15 September 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (6), 2166-2172
- https://doi.org/10.1182/blood-2006-12-061697
Abstract
Increased platelet activation is recognized in patients with sickle cell disease (SCD), but its pathogenesis and clinical relevance remain uncertain. Pulmonary arterial hypertension (PAH), an important complication of SCD, is characterized by a proliferative pulmonary vasculopathy, in situ thrombosis, and vascular dysfunction related to scavenging of nitric oxide (NO) by hemoglobin released into blood plasma during intravascular hemolysis. We investigated links between platelet activation, PAH and NO scavenging in patients with SCD. Platelet activation marked by activated fibrinogen receptor correlated to the severity of PAH (r = 0.58, P < .001) and to laboratory markers of intravascular hemolysis, such as reticulocyte count (r = 0.44, P = .02). In vitro exposure of platelets to pathologically relevant concentrations of cell-free hemoglobin promoted basal- and agonist-stimulated activation and blocked the inhibitory effects on platelet activation by an NO donor. In patients with SCD, administration of sildenafil, a phosphodiesterase-5 inhibitor that potentiates NO-dependent signaling, reduced platelet activation (P = .01). These findings suggest a possible interaction between hemolysis, decreased NO bioavailability, and pathologic platelet activation that might contribute to thrombosis and pulmonary hypertension in SCD, and potentially other disorders of intravascular hemolysis. This supports a role for NO-based therapeutics for SCD vasculopathy. This trial was registered at www.clinicaltrials.gov as no. NCT00352430.Keywords
This publication has 62 references indexed in Scilit:
- Course of Platelet Activation and Platelet-Leukocyte Interaction in Cerebrovascular IschemiaStroke, 2006
- Pulmonary hypertension in thalassemia: Association with platelet activation and hypercoagulable stateAmerican Journal of Hematology, 2006
- Cerebrovascular disease associated with sickle cell pulmonary hypertensionAmerican Journal of Hematology, 2006
- Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregationBiochemical and Biophysical Research Communications, 2005
- The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5Cellular Signalling, 2005
- Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell DiseaseThe New England Journal of Medicine, 2004
- A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunctionBritish Journal of Clinical Pharmacology, 2002
- Activated platelet aggregates in thrombotic thromboctyopenic purpura: decrease with plasma infusions and normalization in remissionBritish Journal of Haematology, 1996
- The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human ??-thrombinBlood Coagulation & Fibrinolysis, 1996
- Biosynthesis and Metabolism of Endothelium-Derived Nitric OxideAnnual Review of Pharmacology and Toxicology, 1990